-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: China
BIO’s Intellectual Property Counsels Committee Seattle Meeting Topics
Join us for BIO’s Intellectual Property Counsels Committee Meeting in Seattle April 13-15. You can find the session topics below. Whose Rights Are They, Anyway? Implications from and a Discussion on Stanford v. Roche The pending Supreme Court review of Stanford v. Roche has brought out multiple perspectives on the disposition of ownership rights in federally funded inventions under Bayh-Dole. This session will explore the different interpretations of the Act’s provisions, and their practical implications Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bill and Melinda Gates Foundation, BIO, biosimilars, biotechnology, Brazil, China, double patenting, emerging markets, Erik Iverson, ethics, Gates Foundation, humanitarian, in house IP attorneys, India, Intellctual Property, Intellectual Property Counsels, IP Counsels' Committee, Korea, Myriad, Patent Agents, research collaborations, Seattle, Stanford v. Roche
Tags: Bill and Melinda Gates Foundation, BIO, biosimilars, biotechnology, Brazil, China, double patenting, emerging markets, Erik Iverson, ethics, Gates Foundation, humanitarian, in house IP attorneys, India, Intellctual Property, Intellectual Property Counsels, IP Counsels' Committee, Korea, Myriad, Patent Agents, research collaborations, Seattle, Stanford v. Roche
A Partner in Partnering: BIO and the China Healthcare Investment Conference
If you’re attending the China Healthcare Investment Conference this month, you’ll probably notice something familiar. BIO has partnered with the Lychee Group to use the One-on-One Partnering System during their event! The event focuses on the most influential Chinese and global thought leaders to promote the development of the Chinese healthcare market, and all attendees will now be able to send requests, schedule meetings, and connect with one another in private meetings. As with all Read More >
BIO Comments to USTR on 2011 Special 301 Review
BIO Comments to USTR on 2011 Special 301 Review (February 15, 2011) In comments to the U.S. Trade Representative (USTR), BIO stresses the critical importance of protecting intellectual property abroad and made recommendations about which countries to include on the Priority Watch and Watch List, which to elevate as a Priority Foreigh Country, and which countries to monitor. Read the Comments (link to http://bio.org/pdfs/BIO_2011_Special_301_Submission.pdf) Read the Press Release (link to http://bio.org/news/pressreleases/newsitem.asp?id=2011_0221_01)
GE Rice in China
This week, Singularity Hub writes about Genetically modified or genetically engineered (GE) rice in China. “China grows a lot of rice – about 60 million tonnes a year. It also consumes most of that, only exporting around 1% of its crop. So, high demand for production with little fear of export restrictions? Sounds like a recipe for genetic modification. According to Reuters, China recently approved the commercial use of genetically modified rice and corn to Read More >
